Maternal serum activin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy

Fetal Diagnosis and Therapy

Volumn 25, Issue 3, 2009, Pages 320-327

  Akolekar, Ranjit ^a   Etchegaray, Adolfo ^a   Zhou, Yi ^a   Maiz, Nerea ^a   Nicolaides, Kypros H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Activin A; First trimester screening; Preeclampsia; Uterine artery Doppler

Indexed keywords

ACTIVIN A; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MATERNAL SERUM; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE;

ACTIVINS; ADULT; CASE-CONTROL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

EID: 70349559643     PISSN: 10153837     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235878     Document Type: Article

References (44)

1. Petraglia F: Inhibin, activin and follistatin in the human placenta - a new family of regulatory proteins. Placenta 1997; 18: 3-8.
2. Florio P, Cobellis L, Luisi S, Ciarmela P, Severi FM, Bocchi C, Petraglia F: Changes in inhibins and activin secretion in healthy and pathological pregnancies. Mol Cell Endocrinol 2001; 180: 123-130.
3. Muttukrishna S, Child TJ, Groome NP, Ledger WL: Source of circulating levels of inhibin A, pro alpha C-containing inhibins and activin A in early pregnancy. Hum Reprod 1997; 12: 1089-1093.
4. Petraglia F, De Vita D, Gallinelli A, Aguzzoli L, Genazzani AR, Romero R, Woodruff TK: Abnormal concentration of maternal serum activin-A in gestational diseases. J Clin Endocrinol Metab 1995; 80: 558-561.
5. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL: Activin A and inhibin A as possible endocrine markers for preeclampsia. Lancet 1997; 349: 1285-1288.
6. Silver HM, Lambert-Messerlian GM, Star JA, Hogan J, Canick JA: Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic, and nonproteinuric gestationally hypertensive pregnancies. Am J Obstet Gynecol 1999; 180: 1131-1137.
7. D'Antona D, Reis FM, Benedetto C, Evans LW, Groome NP, de Kretser DM, Wallace EM, Petraglia F: Increased maternal serum activin A but not follistatin levels in pregnant women with hypertensive disorders. J Endocrinol 2000; 165: 157-162.
8. Yair D, Eshed-Englender T, Kupferminc MJ, Geva E, Frenkel J, Sherman D: Serum levels of inhibin B, unlike inhibin A and activin A, are not altered in women with preeclampsia. Am J Reprod Immunol 2001; 45: 180-187.
9. Manuelpillai U, Schneider-Kolsky M, Dole A, Wallace EM: Activin A and activin receptors in gestational tissue from preeclamptic pregnancies. J Endocrinol 2001; 171: 57-64.
10. Keelan JA, Taylor R, Schellenberg JC, Groome NP, Mitchell MD, North RA: Serum activin A, inhibin A, and follistatin concentrations in preeclampsia or small for gestational age pregnancies. Obstet Gynecol 2002; 99: 267-274.
11. Florio P, Ciarmela P, Luisi S, Palumbo MA, Lambert-Messerlian G, Severi FM, Petraglia F: Pre-eclampsia with fetal growth restriction: Placental and serum activin A and in- hibin A levels. Gynecol Endocrinol 2002; 16: 365-372.
12. Bersinger NA, Smárason AK, Muttukrishna S, Groome NP, Redman CW: Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens Pregnancy 2003; 22: 45-55.
13. Diesch CH, Holzgreve W, Hahn S, Zhong XY: Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia. Prenat Diagn 2006; 26: 1267-1270.
14. Grobman WA, Wang EY: Serum levels of activin A and inhibin A and the subsequent development of preeclampsia. Obstet Gynecol 2000; 96: 390-394.
15. Davidson EJ, Riley SC, Roberts SA, Shearing CH, Groome NP, Martin CW: Maternal serum activin, inhibin, human chorionic gonadotrophin and alpha-fetoprotein as second trimester predictors of pre-eclampsia. BJOG 2003; 110: 46-52.
16. Florio P, Reis FM, Pezzani I, Luisi S, Severi FM, Petraglia F: The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2003; 21: 165-169.
17. Ong CY, Liao AW, Munim S, Spencer K, Nicolaides KH: First-trimester maternal serum activin A in pre-eclampsia and fetal growth restriction. J Matern Fetal Neonatal Med 2004; 15: 176-180.
18. Ay E, Kavak ZN, Elter K, Gokaslan H, Pekin T: Screening for pre-eclampsia by using maternal serum inhibin A, activin A, human chorionic gonadotropin, unconjugated estriol, and alpha-fetoprotein levels and uterine artery Doppler in the second trimester of pregnancy. Aust N Z J Obstet Gynaecol 2005; 45: 283-288.
19. Madazli R, Kuseyrioglu B, Uzun H, Uludag S, Ocak V: Prediction of preeclampsia with maternal mid-trimester placental growth factor, activin A, fibronectin and uterine artery Doppler velocimetry. Int J Gynaecol Obstet 2005; 89: 251-257.
20. Spencer K, Yu CK, Savvidou M, Papageorghiou AT, Nicolaides KH: Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy- associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation. Ultrasound Obstet Gynecol 2006; 27: 658-663.
21. Banzola I, Farina A, Concu M, Sekizawa A, Purwosunu Y, Strada I, Arcelli D, Simonazzi G, Caramelli E, Rizzo N: Performance of a panel of maternal serum markers in predicting preeclampsia at 11-15 weeks' gestation. Prenat Diagn 2007; 27: 1005-1010.
22. Spencer K, Cowans NJ, Nicolaides KH: Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 622-626.
23. Khong TY, De Wolf F, Robertson WB, Brosens I: Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-forgestational age infants. Br J Obstet Gynaecol 1986; 93: 1049-1059.
24. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, van Assche A: Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991; 98: 648-655.
25. Roberts JM, Redman CW: Pre-eclampsia: More than pregnancy-induced hypertension. Lancet 1993; 341: 1447-1451.
26. Redman CWG: Pre-eclampsia and the placenta. Placenta 1991; 12: 301-308.
27. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA: Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001; 38: 718-722.
28. Bearfield C, Jauniaux E, Groome N, Sargent IL, Muttukrishna S: The effect and secretion of inhibin A, activin A and follistatin on first trimester trophoblasts in vitro. Eur J Endocrinol 2005; 152: 909-916.
29. Muttukrishna S, Hyett J, Paine M, Moodley J, Groome N, Rodeck C: Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients. Clin Endocrinol (Oxf) 2006; 64: 469-473.
30. Mohan A, Asselin J, Sargent IL, Groome NP, Muttukrishna S: Effect of cytokines and growth factors on the secretion of inhibin A, activin A and follistatin by term placental villous trophoblasts in culture. Eur J Endocrinol 2001; 145: 505-511.
31. Leal AM, Poon LCY, Frisova V, Veduta A, Nicolaides KH: First-trimester maternal serum tumor necrosis factor receptor-1 and preeclampsia. Ultrasound Obstet Gynecol 2009; 33: 135-141.
32. Tannetta DS, Muttukrishna S, Groome NP, Redman CW, Sargent IL: Endothelial cells and peripheral blood mononuclear cells are a potential source of extraplacental activin a in preeclampsia. J Clin Endocrinol Metab 2003; 88: 5995-6001.
33. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH: Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007; 30: 742-749.
34. Poon LCY, Maiz N, Valencia C, Plasencia W, Nicolaides KH: First-trimester maternal serum PAPP-A and preeclampsia. Ultrasound Obstet Gynecol 2009; 33: 23-33.
35. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346.
36. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH: Screening for trisomy 21 by maternal age, fetal NT, free beta-hCG and PAPP-A. Ultrasound Obstet Gynecol 2008; 31: 618-624.
37. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-XIV.
38. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH: First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: Impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-502.
39. Lawrence JB, Oxvig C, Overgaard MT, Sottrup- Jensen L, Gleich GJ, Hays LG, Yates JR 3rd, Conover CA: The insulin-like growth factor (IGF)-dependent IGF binding protein- 4 protease secreted by human fibroblasts is pregnancy-associated plasma protein- A. Proc Natl Acad Sci USA 1999; 96: 3149-3153. (Pubitemid 29148859)
40. Bonno M, Oxvig C, Kephart GM, Wagner JM, Kristensen T, Sottrup-Jensen L, Gleich GJ: Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy- associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. Lab Invest 1994; 71: 560-566.
41. Irwin JC, Suen LF, Martina NA, Mark SP, Giudice LC: Role of the IGF system in trophoblast invasion and pre-eclampsia. Hum Reprod 1999; 14(suppl 2):90-96.
42. Petraglia F, Aguzzoli L, Gallinelli A, Florio P, Zonca M, Benedetto C, Woodruff K: Hypertension in pregnancy: Changes in activin A maternal serum concentration. Placenta 1995; 16: 447-454.
43. Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J, Ledger W, Groome N, Redman CW: Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod 2000; 15: 1640-1645.
44. Khalil A, Jauniaux E, Harrington K, Muttukrishna S: Placental production and maternal serum and urine levels of inhibin A and activin A are modified by antihypertensive therapy in hypertensive disorders of pregnancy. Clin Endocrinol (Oxf) 2009; 70:924-931.